USD 149.00
The image shown is of one product, in a single vial. Slight variations in colour are to be expected in the final product.
This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
This is a cutting-edge triple receptor agonist targeting GLP-1, GIP and Glucagon
receptors showing exceptional promise for weight loss and metabolic health, with clinical
trials reporting up to 24% weight reduction over 48 weeks. By targeting multiple metabolic
pathways, it enhances energy expenditure, curbs appetite, and improves insulin sensitivity.
Ideal for individuals struggling with obesity or metabolic syndrome seeking next-generation,
research-backed therapeutic options under medical supervision.
Potential Benefits
Improves glucose and lipid metabolism, supporting long-term cardiometabolic wellness.
Promotes liver health, with potential benefits for nonalcoholic fatty liver disease (NAFLD).
Enhances energy expenditure and curb appetite.
Demonstrated superior efficacy compared to single-agonist therapies such as semaglutide in early-phase studies.
**Certificate of Analysis: Available upon request.
